Sign In
Buy TLTFF
$0.166
+0.0001 (+0.0602%)
At Close: Jun 23, 2026
Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options
05:00pm, Tuesday, 24'th Sep 2024
TORONTO, ON / ACCESSWIRE / September 24, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the researc
Theralase(R) Extends Warrants
05:05pm, Thursday, 19'th Sep 2024
TORONTO, ON / ACCESSWIRE / September 19, 2024 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research
Theraalse Technologies highlights Rudivar's superior efficacy in preclinical HSV-1 research
08:47am, Tuesday, 03'rd Sep 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) reported that its lead drug formulation Rudivar has been shown to be more effective than the currently approved standard of care drug Acyclovir in d
Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus
07:00am, Tuesday, 03'rd Sep 2024
Theralase® Technologies Inc. is currently seeking partnerships / licensing opportunities in the commercial development of this latest discovery TORONTO, ON / ACCESSWIRE / September 3, 2024 / Theralas
Theralase Technologies' Rutherrin shows promise against chemoresistance – ICYMI
10:04am, Saturday, 31'st Aug 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) CEO Roger Dumoulin-White talked with Proactive about the company's recent advancements in cancer treatment with its lead compound Rutherrin. Dumou
Theralase Technologies' Rutherrin shows promise in tacking chemoresistance in lung cancer
09:21am, Wednesday, 28'th Aug 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that its lead drug formulation Rutherrin has been shown to provide a “significant” enhancement to the efficacy of cancer therapy Cispl
Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer
07:00am, Wednesday, 28'th Aug 2024
TORONTO, ON / ACCESSWIRE / August 28, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research a
Theralase Technologies CEO discusses innovative cancer therapy Rutherrin – ICYMI
09:29am, Saturday, 24'th Aug 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) CEO Roger DuMoulin-White joined Proactive to discuss the latest advancements in the company's cancer treatment research. DuMoulin-White detailed the
Theralase Technologies Inc. (TLTFF) Q2 2024 Earnings Call Transcript
01:58pm, Wednesday, 21'st Aug 2024
Theralase Technologies Inc. (OTCQX:TLTFF) Q2 2024 Earnings Conference Call August 21, 2024 11:00 AM ET Company Participants Matthew Perraton - Chairman of the Board Kristina Hachey - Chief Financial O
Theralase Technologies reports ability to activate Rutherrin with diabetes drug
09:09am, Wednesday, 21'st Aug 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that its lead drug formulation Rutherrin has been shown preclinically to be activated by the common diabetes drug Metformin without the u
Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug
07:00am, Wednesday, 21'st Aug 2024
TORONTO, ON / ACCESSWIRE / August 21, 2024 / Theralase® Technologies Inc. ("Theralase® " or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research
Theralase nears completion of bladder cancer study with promising results - ICYMI
03:32pm, Friday, 16'th Aug 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) recently announced significant progress in the company's bladder cancer clinical study, now involving 72 patients, with expectations to reach 85 by
Theralase Technologies bladder cancer study achieves key milestones
08:43am, Monday, 12'th Aug 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF), a pioneer in the research and development of light and/or radiation-activated small molecules targeting cancers, bacteria and viruses, has reported
Theralase(R) Release's 2Q2024 Financial Statements
07:00am, Monday, 12'th Aug 2024
TORONTO, ON / ACCESSWIRE / August 12, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research a
Theralase Technologies reports Rutherrin boosts effectiveness of non-cancer drugs in cancer therapy
09:08am, Thursday, 20'th Jun 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that its lead drug formulation Rutherrin was able to repurpose non-cancer drugs for cancer therapy in preclinical research. The company, w
